One out of every three deaths in women is due to cardiovascular disease in the United States. Deaths are more in women compared with men. Coronary heart disease, high blood pressure, cerebrovascular disease, peripartum cardiomyopathy, peripheral vascular disease and congestive heart failure diseases come under the category of cardiovascular diseases. Risk factors for cardiovascular disease specific to women are
Sometimes women may experience unrecognized symptoms of cardiovascular diseases such as fatigue, heartburn and shortness of breath. Daily exercise and proper diet reduces cholesterol and blood pressure levels and causes a reduction in risk of cardiovascular disease.
Deaths due to heart disease is a leading cause of death in spite of increasing awareness of the risk factors. Experts say lives and medical costs could be saved if people follow at least 5 out of 7 following heart-healthy habits with decreased health risks
The study findings were published in the Journal of the American Heart Association Circulation
Intarcia Therapeutics, manufacturers of ITCA 650, a new type 2 diabetes drug have announced that their New Drug Application (NDA) was accepted by FDA for active review.
Ertugliflozin is a type ii diabetes drug (T2D) for adults. This drug works by blocking SGLT2 protein belonging to kidneys. SGLT2 protein injects filtered blood glucose or sugar collected by kidneys back into the bloodstream. As the ertugliflozin drug blocks SGLT2 protein function, more glucose or sugar will be removed from blood via urine by kidneys. Studies show improved A1C control in adult type 2 diabetes (T2D) patients. Latest VERTIS MONO trial results for ertugliflozin, a SGLT2 inhibitor jointly developed by Merck and Pfizer published in the journal Diabetes shows improved A1C control, 4 to 4.5 pounds of weight loss and lower blood pressure (or hypertension) in adult patients with type 2 diabetes (T2D). 461 type ii diabetes (T2D) individuals participated in this VERTIS MONO trial. Following applications along with study results were filed for drug approval
Ertugliflozin oral drug was approved by the FDA on December 20, 2017. This drug will be sold under the brand name Steglatro. Other SGLT2 inhibitors similar to ertugliflozin were
A study done by researchers from the University of Texas Health Science Center, San Antonio, United States shows improved mortality in more than 65 years old type ii diabetes (T2D) patients. The study shows prevention of diseases such as cancer, depression, cardiovascular disease and dementia. Risk reduction varies according to individual's risk among diabetes patients. The researchers concluded that further studies are required to find out the role of metformin. One of the participants in the study was Chen-Pin Wang PhD and the study findings were published online in the Journal of Diabetes and its Complications.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.